Elixir Medical Announces Schedule of Programs for TCT 2014

First Live Case Transmission in the US of the CE Mark-approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

Transcatheter Cardiovascular Technologies Conference

SUNNYVALE, Calif.--()--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will project the first live transmission case demonstration in the USA of its breakthrough and CE Mark-approved DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System at the 26th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Tuesday, Sept. 16. This follows on the heels of a live case transmission on Saturday, Sept. 13th with the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System. The Elixir-sponsored symposium is scheduled on Monday, Sept. 15.

Elixir will also announce new and long-term data on its DESolve Novolimus eluting scaffold and DESyne and DESyne BD stent systems during the scientific conference. Following are the details of Elixir Medical’s programs and activities at TCT in Eastern Standard Time (EST):

Saturday, Sept. 13:

10 am, Washington Convention Center, Main Arena Coronary Theater IV

LIVE CASE from Antwerp Cardiovascular Center, Antwerp, Belgium

DESolve

 

Saturday, Sept. 13:

5 – 7 pm, Washington Convention Center, Lower Level, Hall A

Poster Presentations
 

Abstract 586: Multi-Center, Prospective, Randomized, Single-Blind, Consecutive Enrollment Evaluation of the Elixir DESyne® BD Novolimus Eluting Coronary Stent System with Biodegradable Polymer Compared to a Zotarolimus-Eluting Coronary Stent System: 3-Year Results from the EXCELLA BD Study

 

Abstract 593: Multi-Center, Prospective, Randomized, Single-Blind, Consecutive Enrollment Evaluation of the Elixir DESyne® Novolimus-Eluting Coronary Stent System with Durable Polymer Compared to the Endeavor Zotarolimus-Eluting Coronary Stent System: Final Results from the EXCELLA II Study

 

Monday, Sept 15:

1 – 2 pm, Washington Convention Center, Lower Level, Hall B, Presentation Theater

Elixir-sponsored Symposium: Innovating Vascular Restoration with the DESolve Novolimus Eluting Scaffold Platforms

 

Chairs

-- Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
-- Martin B. Leon, MD, New York – Presbyterian Hospital / Columbia University Medical Center, New York, NY, USA
 

Faculty

-- Professor Dr. med. Holger Nef, Head of the Cardiac Catheterization Laboratory, University Hospital Giessen, Giessen, Germany
-- John Ormiston, MBChB, Mercy Angiographic Unit, Auckland, New Zealand
-- Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium
 

Space is limited: Please register in advance at www.tctconference.com/satelliteprograms.

 

Monday, Sept. 15:

3:20 pm, Level 1; Room 151 A/B

Session II: Current and Emerging Bioabsorbable Polymer Based DES

Novolimus Eluting from a Bioabsorbable Polymer: Latest Update from EXCELLA II

-- Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium
 

Tuesday, Sept. 16:

11 am, Washington Convention Center, Main Arena Coronary Theater IV

LIVE CASE from Thoraxcenter, ERASMUS Medical Center, Rotterdam, Netherlands

DESolve 100

 

Tuesday, Sept. 16:

Session III: BRS Program Update, Level 1, Room 151 A/B
 
3:40 pm, BRS with Clinical Data I DESolve: Differentiating Features and Clinical Update
-- Stefan Verheye, MD, PhD, ZNA Middleheim Hospital, Antwerp, Belgium
 
3:48 pm, TCT 610: Prospective, Multi Center Evaluation of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold: Imaging Outcomes and 2 Year Clinical Results
-- Alexandre Abizaid, MD, PhD, Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil
 

Elixir Medical will have a booth at TCT: Booth 1354, Exhibit Hall. The booth will be open Sunday, Sept. 14 and Monday, Sept. 15 from 9 am to 5 pm, and Tuesday, Sept. 16 from 9 am to 2 pm.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com.

Contacts

Elixir Medical Corporation
Vinayak Bhat, Ph.D., 408-636-2006

Release Summary

Elixir to Transmit First Live Case Demo in the US of the CE Mark-approved Fully Bioresorbable DESolve 100 Novolimus Eluting Coronary Scaffold System

Contacts

Elixir Medical Corporation
Vinayak Bhat, Ph.D., 408-636-2006